Company / Profit Margin
Adaptimmune Therapeutics PLC Profit Margin History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Profit Margin
-39.8%
FY2024
5-year range
-3286.8% / -39.8%
FY2020-FY2024
Trend
+78.9%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Profit Margin has increased for 5 consecutive years, from -12225.0% in FY2019 to -39.8% in FY2024.
Based on SEC 10-K filings.
-39.8% in FY2024 with a 5-year CAGR of +12185.3%.
Improved from -609.5% to -39.8% over the past 2 years.
Profit Margin over time
Growth rates
- 3-Year Change
- +2531.2pp
- 5-Year Change
- +12185.3pp
- 10-Year Change
- -
Key checks
Key Insights
- Adaptimmune Therapeutics PLC's profit margin has grown for 5 consecutive years.
- In FY2024, profit margin increased 78.9% year-over-year.
- Lowest profit margin in the period was in FY2019.
Company context
Key Data Points
- Altman Z-Score -3.53 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Profit MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -39.8% | +78.9% |
| FY2023 | -188.9% | +69.0% |
| FY2022 | -609.5% | +76.3% |
| FY2021 | -2571.0% | +21.8% |
| FY2020 | -3286.8% | +73.1% |
| FY2019 | -12225.0% | -7516.4% |
| FY2018 | -160.5% | +13.4% |
| FY2017 | -185.4% | +63.2% |
| FY2016 | -504.2% | - |
As of FY2024 · SEC 10-K · Updated Jun 29, 2026